GYNECOLOGY

Imunoglobulinele intravenoase și avortul spontan: o analiză narativă

Intravenous immunoglobulins and spontaneous abortion: a narrative review

Dan Navolan, Raluca Pârvănescu, Daniel Șoavă, Mihai Mitran
Data publicării: 02 Iulie 2026
Data primire articol: 02 Iunie 2026
Data acceptare articol: 09 Iunie 2026
Editorial Group: MEDICHUB MEDIA
10.26416/Gine.52.2.2026.11628
Descarcă pdf

Abstract

Spontaneous abortion afflicts 10-20% of clinically re­cog­nized pregnancies and remains a major reproductive chal­lenge. While chromosomal abnormalities account for many cases, up to half of recurrent pregnancy losses (RPL) remain unexplained and may involve immune dysregulation. In­tra­ve­nous immunoglobulin (IVIG) therapy has been pro­posed as a potential immunomodulatory treatment for wo­men with RPL, particularly those with autoimmune or allo­im­mune abnormalities. This narrative review syn­the­sizes current evidence regarding the immunological basis of pregnancy loss, the mechanisms of IVIG action, clinical out­comes and controversies surrounding its use.



Keywords
spontaneous abortionimmunomodulatory treatmentautoimmune or alloimmune abnormalities

Rezumat

Avortul spontan afectează 10-20% din sarcinile confirmate clinic și rămâne o provocare majoră în domeniul reproducerii umane. Deși anomaliile cromozomiale sunt responsabile pentru multe dintre aceste cazuri, până la jumătate dintre pierderile recurente de sarcină (RPL) rămân fără o cauză cunoscută și pot implica de­re­glări ale sistemului imunitar. Terapia cu imunoglobuline in­tra­ve­noa­se (IVIG) a fost propusă ca un potențial tratament imu­no­mo­du­la­tor pentru femeile cu pierderi recurente de sar­ci­nă, în special pentru cele care prezintă anomalii autoimune sau allo­imu­ne. Această analiză narativă sintetizează do­ve­zi­le ac­tua­le privind baza imunologică a pierderii sarcinii, me­ca­nis­me­le de acțiune ale terapiei cu imunoglobuline intravenoase, rezultatele cli­ni­ce și controversele legate de utilizarea acestei terapii.

Cuvinte Cheie
avort spontantratament imunomodulatoranomalii autoimune sau alloimune

1. Introduction

Spontaneous abortion, defined as pregnancy loss before 20-22 weeks of gestation, afflicts approximately 10-20% of pregnancies, with recurrent pregnancy loss (RPL) occurring in 1-2% of couples(1,2). Although genetic, anatomical, endocrine and infectious causes are well recognized, nearly 50% of RPL cases remain unexplained(3,4). Increasing evidence suggests that immune dysfunction – including autoimmunity, alloimmune intolerance and abnormal natural killer (NK) cell activity – may contri­bute to pregnancy failure(5,6).

Given its broad immunomodulatory properties, intravenous immunoglobulin (IVIG) has been investigated as a therapeutic option for preventing spontaneous abortion in selected women with RPL(7,8), but the results remain controversial.

2. Immunological basis of spontaneous abortion

Successful pregnancy requires a finely regulated maternal immune response that promotes tolerance toward fetal antigens while maintaining adequate defense mechanisms. Several immunological abnormalities have been associated with miscarriage:

  • Autoimmune disorders, particularly antiphospholipid syndrome (APS) and systemic lupus erythematosus (SLE), are strongly linked to pregnancy loss(9,10).
  • Alloimmune dysfunction, including inadequate maternal tolerance to paternal antigens, may impair implantation and placental development(6).
  • Abnormal NK cell activity, especially elevated cytotoxic uterine NK cells, has been observed in women with RPL(11).
  • Cytokine imbalance, particularly a shift toward a Th1-dominant inflammatory profile, is associated with early pregnancy failure(12).
  • Complement activation, a mechanism implicated in placental injury in autoimmune diseases(13).

These findings provide the rationale for immunomodu­latory therapies such as IVIG.

3. Mechanisms of action of IVIG in pregnancy

IVIG is a purified IgG preparation derived from pooled donor plasma. Its mechanisms of action are diverse, and may support pregnancy maintenance.

3.1. Modulation of NK cell activity

IVIG reduces NK cell cytotoxicity and alters receptor expression, promoting a more tolerant uterine environment(14).

3.2. Cytokine regulation

IVIG shifts the immune response from a Th1-domi­nant to a Th2-dominant profile, which is essential for implantation and placental development(15).

3.3. Fc receptor blockade

By saturating Fc receptors, IVIG reduces the activity of pathogenic autoantibodies and immune complexes, particularly relevant in APS and SLE(16).

3.4. Complement inhibition

IVIG contains anti-idiotypic antibodies that inhibit complement activation, reducing inflammation at the maternal-fetal interface(17).

3.5. Enhancement of regulatory T cells

Regulatory T cells (Tregs) are essential for maternal tolerance; IVIG has been shown to increase their number and function(18).

These mechanisms collectively support the hypothe­sis that IVIG may benefit women with immunemediated pregnancy loss.

3.6. Anti-immunoglobulin antibodies – anti-idiotype and anti-F(ab)2 antibodies

Idiotype anti‑idiotype networks create a natural regulatory loop in which antibodies neutralize each other’s antigen‑binding sites, dampening excessive immune activation. Anti‑idiotype antibodies can mimic fetal antigens and induce tolerance by promoting regulatory T‑cell expansion and reducing Th1‑type inflammation(19). Anti‑F(ab’)2 antibodies further down‑regulate autoreactive B‑cell clones by binding to their antigen‑binding fragments, limiting harmful autoantibody production(20). Together, these mechanisms reduce NK‑cell cytotoxicity, complement activation and inflammatory cytokines at the maternal-fetal interface. This immunomodulation explains why IVIG – rich in anti‑idiotype and anti‑F(ab’)2 antibodies – may help restore immune tolerance in women with recurrent spontaneous abortion of suspected immune origin(21).

4. Clinical evidence for IVIG in preventing spontaneous abortion

4.1. IVIG in autoimmune-related pregnancy loss

In APS, standard therapy consists of low-dose aspirin and heparin, which significantly improve the outcomes(22). IVIG has been used as an adjunct in refractory cases, with some studies reporting improved live birth rates(23).

4.2. IVIG in unexplained recurrent pregnancy loss (uRPL)

This is the most debated indication. Early uncontrolled studies suggested live birth rates of 70-80% with IVIG(7). However, randomized controlled trials (RCTs) have produced mixed results:

  • Some RCTs found no significant benefit compared with placebo(24).
  • Others demonstrated improved outcomes in specific subgroups, such as women with more than three miscarriages(25).

A 2021 metaanalysis concluded that IVIG may improve live birth rates in selected high-risk women, but heterogeneity across studies limits firm conclusions(26).

4.3. IVIG in alloimmune disorders

Women with abnormal alloimmune profiles (e.g., low blocking antibodies, high Th1/Th2 ratios) may benefit from IVIG, although these tests lack standardization(27).

4.4. Timing and dosage

Protocols vary widely:

  • Early pregnancy administration (peri-implantation) appears more effective(24).
  • Doses range from 0.2 g/kg to 1 g/kg, given monthly or biweekly(28).

Lack of standardization complicates the interpretation of results.

5. Safety and adverse effects

IVIG is generally well tolerated. Common adverse effects include headache, fever and chills, while rare complications include thromboembolic events, aseptic meningitis and hemolysis(29).

In pregnancy, IVIG is considered relatively safe, with no evidence of teratogenicity(30).

6. Controversies and limitations

6.1. Heterogeneity of patient populations

Studies include women with autoimmune, alloimmune and unexplained RPL, making comparisons difficult(7,12).

6.2. Lack of standardized immunological testing

Markers such as NK cell levels or cytokine ratios vary by laboratory and lack universal cutoffs(11,12).

6.3. High cost and resource use

IVIG is expensive and requires infusion facilities, raising concerns about cost-effectiveness(32).

6.4. Ethical considerations

Major reproductive societies, including ASRM and ESHRE, do not recommend routine IVIG use outside research settings due to insufficient evidence(33,34).

7. Future directions

Future research should focus on:

  • Identifying reliable biomarkers to select women who may benefit(21,35).
  • Standardizing IVIG protocols (dose, timing, duration)(25).
  • Conducting large RCTs targeting immunologically defined subgroups(25).
  • Exploring alternative immunotherapies (e.g., intralipid therapy, TNF-a inhibitors, Treg-based therapies)(36,37).

8. Conclusions

Intravenous immunoglobulin is a promising but controversial therapy for preventing spontaneous abortion, particularly in women with recurrent pregnancy loss of suspected immunological origin. While mechanistic studies support its potential benefits, clinical evidence remains inconsistent due to heterogeneous study designs and patient populations. At present, IVIG should be considered only in selected high-risk cases or within clinical research protocols. Continued investigation is essential to clarify which women may truly benefit and to establish standardized treatment guidelines.

  

 

Autor corespondent:   Dan Navolan E-mail: navolan@yahoo.com 

  

 

CONFLICT OF INTEREST: none declared.

FINANCIAL SUPPORT: none declared.

This work is permanently accessible online free of charge and published under the CC-BY.

 

Bibliografie


  1. Branch DW, Gibson M, Silver RM. Clinical Practice. Recurrent miscarriage. N Engl J Med. 2010;363(18):17407. 
  2. Christiansen OB, Nielsen HS, Kolte AM. Future directions of failed implantation and recurrent miscarriage research. Reprod Biomed Online. 2006;13(1):7183. 
  3. Clark DA, Coulam CB, Stricker RB. Is intravenous immunoglobulins (IVIG) efficacious in early pregnancy failure? A critical review and meta-analysis for patients who fail in vitro fertilization and embryo transfer (IVF). J Assist Reprod Genet. 2006;23(1):1-13. 
  4. Stephenson MD, Kutteh WH. Evaluation and management of recurrent early pregnancy loss. Clin Obstet Gynecol. 2007;50(1):13245. 
  5. Jaslow CR, Carney JL, Kutteh WH. Diagnostic factors in 1020 women with recurrent pregnancy loss. Fertil Steril. 2010;93(4):123443. 
  6. Bagkou Dimakou D, Lissauer D, Tamblyn J, Coomarasamy A, Richter A. Understanding human immunity in idiopathic recurrent pregnancy loss. Eur J Obstet Gynecol Reprod Biol. 2022;270:17-29.
  7. Wong LF, Porter TF, Scott JR. Immunotherapy for recurrent miscarriage. Cochrane Database Syst Rev. 2014;(10):CD000112. 
  8. Kofod L, Pedersen M, Andersen M, Christensen E, Pedersen P, Alipour H, Egerup P, Christiansen OB, Kesmodel US. Intravenous immunoglobulin versus placebo in recurrent pregnancy loss: A systematic review and meta-analysis of randomized trials. J Reprod Immunol. 2025;170:104541. 
  9. Salmon JE, de Groot PG. Pathogenic role of antiphospholipid antibodies. Lupus. 2008;17(5):40511.
  10. Branch DW, Silver RM, Porter TF. Obstetric antiphospholipid syndrome: current uncertainties should guide our way. Lupus. 2010;19(4):446-52.
  11. Salazar MD, Wang WJ, Skariah A, He Q, Field K, Nixon M, Reed R, Dambaeva S, Beaman K, Gilman-Sachs A, Kwak-Kim J. Post-hoc evaluation of peripheral blood natural killer cell cytotoxicity in predicting the risk of recurrent pregnancy losses and repeated implantation failures. J Reprod Immunol. 2022;150:103487. 
  12. Kargar R, Yahoo Z, Rafiemanesh H, Aslani S, Shamosi A, Mohammadi H. Evaluation of Th1-Th2 balance in patients with unexplained recurrent spontaneous abortion: a systematic review and meta-analysis. Am J Reprod Immunol. 2025;94(1):e70125. 
  13. Roy T, Das A, Chatterjee N, Saha SP, Prasad R, Madan T, Yasmin H, Kishore U. Differential expression of complement Properdin and Factor H in the placentae and umbilical cords of mothers with Preeclampsia, Gestational diabetes mellitus and recurrent pregnancy loss. Front Immunol. 2026;16:1731251.
  14. Dons’koi B, Kononenko I, Sirenko V, Bodnar N, Serbyn A, Kozachok A, Brovarska Y. Intravenous immunoglobulin or intravenous lipid emulsion therapy in patients with elevated NK cytotoxicity improves live birth rates in different ways. Am J Reprod Immunol. 2025;94(4):e70176. 
  15. Ahmadi M, Abdolmohammadi-Vahid S, Ghaebi M, Aghebati-Maleki L, Afkham A, Danaii S, Abdollahi-Fard S, Heidari L, Jadidi-Niaragh F, Younesi V, Nouri M, Yousefi M. Effect of Intravenous immunoglobulin on Th1 and Th2 lymphocytes and improvement of pregnancy outcome in recurrent pregnancy loss (RPL). Biomed Pharmacother. 2017;92:1095-102. 
  16. Nagelkerke SQ, Kuijpers TW. Immunomodulation by IVIg and the role of Fc-Gamma receptors: classic mechanisms of action after all?. Front Immunol. 2015;5:674. 
  17. Perricone R, De Carolis C, Kröegler B, Greco E, Giacomelli R, Cipriani P, Fontana L, Perricone C. Intravenous immunoglobulin therapy in pregnant patients affected with systemic lupus erythematosus and recurrent spontaneous abortion. Rheumatology (Oxford). 2008;47(5):646-51. 
  18. Saito S, Nakashima A, Shima T, Ito M. Th1/Th2/Th17 and regulatory T-cell paradigm in pregnancy. Am J Reprod Immunol. 2010;63(6):60110.
  19. Terness P, Opelz G. Natural anti-immunoglobulin autoantibodies: irrelevant by products or immunoregulatory molecules?. Int Arch Allergy Immunol. 1998;115(4):270-7.
  20. Terness PI, Navolan D, Dufter C, Welschof M, Opelz G. Immunosuppressive anti-immunoglobulin autoantibodies: specificity, gene structure and function in health and disease. Cell Mol Biol (Noisy-le-grand). 2002;48(3):271-8.
  21. Navolan D, Sas I, Terness P. Intravenous immunoglobulins in reproductive immunology: mechanisms and clinical applications. Farmacia. 2016;64(3):321-327.
  22. Coulam CB, Acacio B. Does immunotherapy enhance live births?. Am J Reprod Immunol. 2012;67(4):296304.
  23. Yuan X, Zhang W, Wang T, Jiang P, Wang ZK, Li CQ. Use of intravenous im­mu­no­globulin in antiphospholipid antibody positive patients with high risk of miscarriage: a systematic review and meta-analysis. PeerJ. 2024;12:e18419. 
  24. Kofod L, Pedersen M, Andersen M, Christensen E, Pedersen P, Alipour H, Egerup P, Christiansen OB, Kesmodel US. Intravenous immunoglobulin versus placebo in recurrent pregnancy loss: A systematic review and meta-analysis of randomized trials. J Reprod Immunol. 2025;170:104541. 
  25. Yamada H, Deguchi M, Saito S, Takeshita T, Mitsui M, Saito T, Nagamatsu T, Takakuwa K, Nakatsuka M, Yoneda S, Egashira K, Tachibana M, Matsubara K, Honda R, Fukui A, Tanaka K, Sengoku K, Endo T, Yata H. Intravenous immu­no­globulin treatment in women with four or more recurrent pregnancy losses: A double-blind, randomised, placebo-controlled trial. EClinicalMedicine. 2022;50:101527. 
  26. Saab W, Seshadri S, Huang C, Alsubki L, Sung N, Kwak-Kim J. A systemic review of intravenous immunoglobulin G treatment in women with recurrent implantation failures and recurrent pregnancy losses. Am J Reprod Immunol. 2021;85(4):e13395. 
  27. Sung N, Han AR, Park CW, Park DW, Park JC, Kim NY, Lim KS, Shin JE, Joo CW, Lee SE, Kim JW, Lee SK; IVIG Task Force, Korean Society for Reproductive Immunology. Intravenous immunoglobulin G in women with reproductive failure: The Korean Society for Reproductive Immunology practice guidelines. Clin Exp Reprod Med. 2017;44(1):1-7. 
  28. Han JW, Park JS, Kim JS, Lee SK. Efficacy of intravenous immunoglobulin in recurrent pregnancy loss: a retrospective analysis of patients with abnormal cellular immunity. Front Endocrinol (Lausanne). 2025;16:1546602
  29. Guo Y, Tian X, Wang X, Xiao Z. Adverse Effects of Immunoglobulin Therapy. Front Immunol. 2018;9:1299. 
  30. Han A, Lee SK, Park JC, Park CW, Han JW, Lee KH. Maternal and fetal safety of intravenous immunoglobulin in women with reproductive failure. Am J Reprod Immunol. 2021;86(6):e13492. 
  31. Yang X, Meng T. Is there a Role of Intravenous Immunoglobulin in Immunologic Recurrent Pregnancy Loss?. J Immunol Res. 2020;2020:6672865. 
  32. Mu F, Huo H, Wang M, Liu L, Wang F. Intravenous immunoglobulin improves live birth rates in patients with unexplained recurrent pregnancy loss. J Reprod Immunol. 2024;166:104322. 
  33. Practice Committee of the American Society for Reproductive Medicine. Re­current pregnancy loss: a committee opinion. Fertil Steril. 2026;125(6):1023-41. 
  34. ESHRE Guideline Group on RPL; Bender Atik R, Christiansen OB, Elson J, Kolte AM, Lewis S, Middeldorp S, Mcheik S, Peramo B, Quenby S, Nielsen HS, van der Hoorn ML, Vermeulen N, Goddijn M. ESHRE guideline: recurrent pregnancy loss: an update in 2022. Hum Reprod Open. 2023;2023(1):hoad002. 
  35. Banjar S, Kadour E, Khoudja R, Ton-Leclerc S, Beauchamp C, Beltempo M, Dahan MH, Gold P, Jacques Kadoch I, Jamal W, Laskin C, Mahutte N, Reinblatt SL, Sylvestre C, Buckett W, Genest G. Intravenous immunoglobulin use in patients with unexplained recurrent pregnancy loss. Am J Reprod Immunol. 2023;90(2):e13737. 
  36. Canella PRBC, Barini R, Carvalho PO, Razolli DS. Lipid emulsion therapy in women with recurrent pregnancy loss and repeated implantation failure: The role of abnormal natural killer cell activity. J Cell Mol Med. 2021;25(5):2290-6. 
  37. Cai Z, Guo X, Zheng G, Xiang J, Liu L, Lin D, Deng X. TNF-α-positive patients with recurrent pregnancy loss: The etiology and management. Technol Health Care. 2024;32(6):4581-91. 
Articole din ediția curentă

Ginecologia.ro
EVENTS

July-September 2026 Calendar

...
Citește mai departe »
Ginecologia.ro
INTERDISCIPLINARY

Dincolo de post: beneficiile metabolice ale postului din Ramadan pentru femeile musulmane

Faiz M.M.T. Marikar, Fatheema Aleena
Postul Ramadanului, practicat de femeile musulmane din în­trea­ga lume, reprezintă o formă de post intermitent înră­dă­ci­na­tă cultural, cu dovezi emergente privind beneficiile pen­tru sănătatea cardiometabolică....
Citește mai departe »
Ginecologia.ro
INTERDISCIPLINARY

Prevenţia suicidului în perioada post-partum

Raluca Pretorian
Tulburarea depresivă post-partum (PPD) este o tulburare de­pre­si­vă majoră....
Citește mai departe »
Articole din edițiile anterioare

Ginecologia.ro
GYNECOLOGY

Eritropoietina – un antioxidant inert pentru organele genitale interne feminine la șobolan

Constantinos Tsompos, Constantinos Panoulis, Constantinos Zografos, George C. Zografos, Apostolos Papalois
Acest studiu a analizat patru cercetări raportate du­pă ad­mi­nis­tra­rea de eritropoietină (Epo). ...
Citește mai departe »
Ginecologia.ro
GYNECOLOGY

Caz atipic de molă hidatiformă completă – prezentare de caz

Marina-Andreea Lungu, Romina-Marina Sima, Liana Pleș, Ileana-Maria Conea
Mola hidatiformă face parte din grupul bolilor trofoblastice gestaționale, care conține mai multe patologii, fiecare cu aceeași origine....
Citește mai departe »
Ginecologia.ro
GYNECOLOGY

Tratamentul fibroamelor uterine: review al literaturii

Oana-Maria Cosma, Delia Grădinaru, Sorin Vasilescu, Octavian Munteanu, Adrian Dumitru, Evelina Stoica, Monica-Mihaela Cîrstoiu
Fibromul uterin este una dintre cele mai frecvente patologii be­nig­ne ale femeii de vârstă fertilă. ...
Citește mai departe »